Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that on January 13, 2025, the Compensation Committee of Acadia’s Board of Directors (the "Committee") granted inducement awards consisting of ...

TD Cowen analyst Ritu Baral maintained a Buy rating on ACADIA Pharmaceuticals (ACAD – Research Report) today and set a price target of $35.00.

With just over 100 days as CEO now under her belt, Catherine Owen Adams is looking to cruise rare disease-focused Acadia ...

Guggenheim has recently reduced ACADIA Pharmaceuticals Inc (ACAD) stock to Neutral rating, as announced on January 3, 2025, according to Finviz. Earlier, on October 10, 2024, Raymond James had resumed ...

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Get Free Report) was the recipient of a large increase in short interest in December. As of December 31st, there was short interest totalling 10,720,000 ...

$510,000 of ACADIA PHARMACEUTICALS lobbying was just disclosed, from Q4 of 2024, in a new Lobbying Disclosure Act filing. This included lobbying on issues like: "Implementation of the Inflation ...

Neuren Pharmaceuticals (ASX:NEU) has announced that its partner Acadia Pharmaceuticals has submitted a Marketing ...

Pacira BioSciences (PCRX) announced two key appointments to its executive leadership team. Brendan Teehan has been named Chief Commercial ...

Radiopharmaceuticals company Telix Pharmaceuticals has provided its Q4 FY24 trading update, showing sustained revenue growth.